IL12A-AS1: A Potential Drug Target and Biomarker (G101928376)

IL12A-AS1: A Potential Drug Target and Biomarker

The immune system is a critical element of our body's defense against infections, viruses, and diseases. The interleukin (IL) family of cytokines plays a vital role in the regulation of immune responses. IL12A-AS1, a cytokine produced by natural killer cells (NK cells), has been identified as a potential drug target and biomarker for various diseases.

IL12A-AS1 is a 14kDa protein that is expressed in various tissues, including the spleen, lymph nodes, and the skin. It is a key member of the IL12 family, which includes several cytokines, including IL12, IL13, and IL14. IL12A-AS1 is characterized by its ability to induce cell-mediated immunity, as well as its role in the regulation of inflammation and immune cell function.

One of the unique features of IL12A-AS1 is its ability to induce potent cell-mediated immunity, including the generation of long-lived memory T cells. This is accomplished through the secretion of IL12, which activates and sustains CD8+ T cell responses. CD8+ T cells are known for their ability to recognize and destroy infected or abnormal cells, making them an attractive target for cancer and other diseases.

IL12A-AS1 has also been shown to play a key role in the regulation of inflammation and autoimmune diseases. Its ability to induce the production of pro-inflammatory cytokines, such as TNF-?± and IL-1??, suggests that it may contribute to the development and progression of these diseases. Additionally, the anti-inflammatory effects of IL12A-AS1 have been reported to be beneficial in treating autoimmune diseases such as rheumatoid arthritis and psoriasis.

In addition to its potential therapeutic applications, IL12A-AS1 is also a promising biomarker for the diagnosis and monitoring of various diseases. Its ability to induce cell-mediated immunity and its potential therapeutic applications make it an attractive target for cancer, autoimmune diseases, and other inflammatory conditions.

IL12A-AS1 has been shown to be involved in the regulation of cellular processes that are critical for immune function, such as T cell development and differentiation, and cytokine regulation. Its role in these processes makes it an important candidate for potential drug targets. Furthermore, its ability to induce cell-mediated immunity and its potential therapeutic applications make it an attractive biomarker for the diagnosis and monitoring of various diseases.

In conclusion, IL12A-AS1 is a promising drug target and biomarker for various diseases. Its ability to induce cell-mediated immunity and its potential therapeutic applications make it an attractive target for cancer, autoimmune diseases, and other inflammatory conditions. Further research is needed to fully understand the role of IL12A-AS1 in these processes and its potential as a drug and biomarker.

Protein Name: IL12A Antisense RNA 1

The "IL12A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL12A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL12B | IL12RB1 | IL12RB2 | IL13 | IL13RA1 | IL13RA2 | IL15 | IL15RA | IL16 | IL17A | IL17B | IL17C | IL17D | IL17F | IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L